Drug Type Monoclonal antibody |
Synonyms Anti-tim-3 monoclonal antibody mbg453, Anti-tim3 checkpoint inhibitor mbg453, Immunoglobulin g4 (226-proline,de-c-terminal-lysine), anti-(human hepatitis virus a cellular receptor 2) (human-mus musculus monoclonal clone nvs260714 .gamma.4-chain), disulfide with human-mus musculus monoclonal clone nvs260714 .kappa.-chain, dimer + [3] |
Target |
Mechanism TIM3 inhibitors(Hepatitis A virus cellular receptor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationFast Track (US), Orphan Drug (EU) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic Myelomonocytic Leukemia | Phase 3 | US | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | CN | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | JP | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | AR | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | AU | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | AT | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | BE | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | BR | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | CA | 08 Jun 2020 | |
Chronic Myelomonocytic Leukemia | Phase 3 | CL | 08 Jun 2020 |
Phase 3 | 530 | nxkxnsduah(drrwokjipi) = broomelukd kwqqrvzdhq (dsyoktqohe ) Not Met View more | Negative | 14 May 2024 | |||
Phase 3 | 530 | mekvgnzlvx(zntjalmtxq) = the late-stage study missed its primary endpoint, overall survival slltgcxfzd (xvuizquyyy ) Not Met | Negative | 31 Jan 2024 | |||
Placebo+Azacitidine | |||||||
Not Applicable | - | Sabatolimab plus hypomethylating agent | qayvnisirq(zwawmogwex) = 22 [35%] vs 34 [54%] bktbhzgbhb (arcfwqzmbe ) View more | - | 01 Jan 2024 | ||
Placebo plus hypomethylating agent | |||||||
Phase 2 | 33 | xpnblhjrdf(jcaxetfnhe) = zlacokuvpd hqmbedpqbu (bgdrbfgtug, 10.7% - 50.2%) View more | - | 11 Dec 2023 | |||
Phase 2 | 127 | Sabatolimab + HMA | (cmawddtoyd) = feijejqucj xnuzdlflub (qivbqeighx ) View more | - | 10 Dec 2023 | ||
Placebo + HMA | (cmawddtoyd) = erwscqvzak xnuzdlflub (qivbqeighx ) View more | ||||||
Phase 2 | 127 | Hypomethylating agents+MBG453 (MBG453 + Hypomethylating Agents) | blnzaeubrz(bqgnpgdhwo) = vsdcyoivry izhgiwixbp (jvjypdqmwv, prjujzwalq - rhkcuegupl) View more | - | 07 Jul 2023 | ||
Placebo (Placebo + Hypomethylating Agents) | blnzaeubrz(bqgnpgdhwo) = tqvzvgvmwa izhgiwixbp (jvjypdqmwv, hpwlalwmli - rizlzhyvxq) View more | ||||||
Phase 2 | 127 | HMA+Sabatolimab | rszivvjpwt(gtitxivekq) = ofwugminxj qcmuwebwrj (czohktficr ) View more | Negative | 15 Nov 2022 | ||
HMA+placebo | rszivvjpwt(gtitxivekq) = epskyvixdn qcmuwebwrj (czohktficr ) View more | ||||||
NCT03066648 (ASH2021) Manual | Phase 1 | 101 | Hypomethylating Agents+Sabatolimab (vHR/HR-MDS) | fnyapmwazv(csclgjdamx) = ocdcfjekym jomgqpsofx (bepqamfwof ) View more | Positive | 05 Nov 2021 | |
Hypomethylating Agent+Sabatolimab (ND-AML) | fnyapmwazv(csclgjdamx) = wtppqfrlkj jomgqpsofx (bepqamfwof ) View more | ||||||
NCT02608268 (Pubmed) Manual | Phase 1 | 219 | qfvaebxguu(bwwnjecscb) = amkdhyidol hrfedlycrr (rknugftrih ) | Positive | 01 Jul 2021 | ||
rlupjithxp(iofevxopbk) = kgkuysmwbw zxqbljqlqk (phmwyirirb ) View more | |||||||
Phase 1 | - | rfcmgogxmx(rpnfhbujsg) = mexymuaqgj uuyisemlwy (valtaarslk ) | - | 10 Dec 2020 |